Dr. Ayyappan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Celebrate Life Pkwy.
Newnan, GA 30265
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 2007 - 2010
Madras Medical CollegeClass of 2004
Certifications & Licensure
GA State Medical License 2023 - 2025
IA State Medical License 2019 - 2025
OH State Medical License 2011 - 2021
MA State Medical License 2010 - 2013
Clinical Trials
- Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors Start of enrollment: 2005 Nov 01
- Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 Start of enrollment: 2022 Mar 17
Publications & Presentations
PubMed
- 39 citationsImaging of musculoskeletal manifestations in sickle cell disease patients.Vijaya Kosaraju, Alok Harwani, Sasan Partovi, Nicholas Bhojwani, Vasant Garg
The British Journal of Radiology. 2017-04-07 - 18 citationsAn international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.Juan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, Anne W Beaven, Anne W Beaven
Blood Advances. 2022-04-12 - 12 citationsAggressive Lymphoma Subtype Is A Risk Factor for Venous Thrombosis. Development of Lymphoma - Specific Venous Thrombosis Prediction Models.Gouri Dharmavaram, Shufen Cao, Suchitra Sundaram, Sabarish Ayyappan, Kirsten M Boughan
American Journal of Hematology. 2020-04-20
Press Mentions
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
